Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Minerva Biotechnologies is raising $30,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Cynthia Bamdad played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Minerva Biotechnologies
Minerva Biotechnologies is developing therapies for curing cancers and commercializing core technology that will enable next generation stem cell therapies. Both flow from Minervas fundamental discovery that both cancer cell and stem cell growth are mediated by the same two molecules: the growth factor NME-p and the growth factor receptor MUC1. Cancer Therapeutics: Minerva discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. We can reverse the reprogramming and make cancer cells differentiate so that cancer growth is turned off. This is a novel approach to curing cancer. We have 3 anti-cancer therapeutics in our pipeline. Regenerative Medicine: Minerva is the first company to generate human nave state pluripotent stem cells using a single, naturally occurring human stem cell growth factor. These earlier stem cells have a clean slate, and are more easily directed to develop into functional mature cells, which could be used for transplant.

To learn more about Minerva Biotechnologies, visit http://www.minervabio.com/

Contact:
Cynthia Bamdad, President and Chief Executive Officer
781-487-0200
https://www.linkedin.com/in/cynthia-bamdad-3717231/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved